---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-257760"
form_type: "8-K"
ticker: "TNGX"
cik: "0001819133"
company_name: "Tango Therapeutics, Inc."
filed_at: "2026-06-04T21:19:05+00:00"
generated_at: "2026-06-04T21:21:41.168511+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Tango Therapeutics annual meeting elects two Class II directors, ratifies auditor, approves NEO compensation

## Summary
- Peters elected with 98,188,796 for; 17,623,596 withheld; Rothenberg with 92,476,172 for; 23,336,220 withheld.
- Ratification of PricewaterhouseCoopers as 2026 auditor: 131,097,992 for, 73,823 against, 26,266 abstain.
- Advisory vote on named executive officer compensation: 113,915,877 for, 1,855,838 against, 40,677 abstain.
- Director Kanishka Pothula resigned effective May 13, 2026 prior to meeting; not a disagreement with company.

## SEC filing metadata
- accession: 0001193125-26-257760
- form_type: 8-K
- ticker: TNGX
- cik: 0001819133
- company_name: Tango Therapeutics, Inc.
- filed_at: 2026-06-04T21:19:05+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819133/000119312526257760/0001193125-26-257760-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819133/000119312526257760/d149262d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-257760
- JSON: https://secwatch.observer/filing/0001193125-26-257760.json
- Plain text: https://secwatch.observer/filing/0001193125-26-257760.txt

## Key facts
- Shareholder Votes
  Tango Therapeutics, Inc. shareholders approved Election of Mace Rothenberg, M.D. as Class II director at the 2026-06-04 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-04
  source text: Malte Peters, M.D. and Mace Rothenberg, M.D. were duly elected to the Company's Board as Class II directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819133/000119312526257760/0001193125-26-257760-index.htm
- Shareholder Votes
  Tango Therapeutics, Inc. shareholders approved Ratification of the selection of PricewaterhouseCoopers, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-04 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-04
  source text: The selection of PricewaterhouseCoopers, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819133/000119312526257760/0001193125-26-257760-index.htm
- Shareholder Votes
  Tango Therapeutics, Inc. shareholders approved Non-binding advisory vote to approve named executive officer compensation at the 2026-06-04 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-04
  source text: The Company's stockholders approved the non-binding, advisory vote on the compensation of the Company's named executive officers.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819133/000119312526257760/0001193125-26-257760-index.htm
- Shareholder Votes
  Tango Therapeutics, Inc. shareholders approved Election of Malte Peters, M.D. as Class II director at the 2026-06-04 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-04
  source text: Malte Peters, M.D. and Mace Rothenberg, M.D. were duly elected to the Company's Board as Class II directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819133/000119312526257760/0001193125-26-257760-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.